Outbreak report of rotavirus gastroenteritis among remotely vaccinated travelers: A potential implication of booster vaccine for travelers to endemic countries.
{"title":"Outbreak report of rotavirus gastroenteritis among remotely vaccinated travelers: A potential implication of booster vaccine for travelers to endemic countries.","authors":"Masayuki Onaka, Taito Kitano, Sayaka Yoshida","doi":"10.1080/21645515.2025.2467475","DOIUrl":null,"url":null,"abstract":"<p><p>In countries in which rotavirus vaccines have been introduced for young infants, the incidence of rotavirus infections has dramatically decreased. This report presents an outbreak of rotavirus gastroenteritis among travelers. Data regarding the long-term protective effect of rotavirus vaccines after years of vaccination are scarce. A Japanese group of 14 children and nine adults traveled to Malaysia over 4 weeks. During travel, 15 of 23 patients developed gastroenteritis symptoms (Figure 1). Stool samples were collected from two symptomatic patients that tested positive for rotavirus. None of the five members with a history of rotavirus gastroenteritis developed symptoms. Nine of the 10 vaccinated children developed symptoms of acute gastroenteritis without the need for hospitalization. The only child without a history of vaccination or infection developed acute gastroenteritis and required hospitalization for continuous intravenous hydration. While individuals with a history of infection did not develop acute gastroenteritis, the protective effects of vaccination against symptomatic infection did not sustain long. This indicates the potential need for a booster dose of the rotavirus vaccine for travelers to rotavirus-endemic countries.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2467475"},"PeriodicalIF":3.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866960/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2025.2467475","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
In countries in which rotavirus vaccines have been introduced for young infants, the incidence of rotavirus infections has dramatically decreased. This report presents an outbreak of rotavirus gastroenteritis among travelers. Data regarding the long-term protective effect of rotavirus vaccines after years of vaccination are scarce. A Japanese group of 14 children and nine adults traveled to Malaysia over 4 weeks. During travel, 15 of 23 patients developed gastroenteritis symptoms (Figure 1). Stool samples were collected from two symptomatic patients that tested positive for rotavirus. None of the five members with a history of rotavirus gastroenteritis developed symptoms. Nine of the 10 vaccinated children developed symptoms of acute gastroenteritis without the need for hospitalization. The only child without a history of vaccination or infection developed acute gastroenteritis and required hospitalization for continuous intravenous hydration. While individuals with a history of infection did not develop acute gastroenteritis, the protective effects of vaccination against symptomatic infection did not sustain long. This indicates the potential need for a booster dose of the rotavirus vaccine for travelers to rotavirus-endemic countries.
期刊介绍:
(formerly Human Vaccines; issn 1554-8619)
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.
Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.